See the DrugPatentWatch profile for ozempic

Ozempic (generic name: semaglutide) is a prescription medication primarily used to improve glycemic control in adults with type 2 diabetes, in combination with diet and exercise. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. While Ozempic is generally well-tolerated, some rare side effects have been reported.

Rare side effects of Ozempic, as reported in its prescribing information, include:

1. Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including Ozempic [${1}].

2. Hypoglycemia: In clinical trials, the incidence of hypoglycemia was higher in patients receiving Ozempic in combination with insulin or sulfonylureas [${1}].

3. Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal impairment in patients treated with GLP-1 receptor agonists, including Ozempic [${1}].

4. Gallbladder Disease: In clinical trials, cholelithiasis (gallstones) was reported more frequently in patients treated with Ozempic [${1}].

5. Diabetic Retinopathy Complications: In a clinical trial, more events of diabetic retinopathy complications occurred in patients treated with Ozempic [${1}].

6. Allergic Reactions: There have been postmarketing reports of serious hypersensitivity reactions, including anaphylaxis and angioedema, with GLP-1 receptor agonists, including Ozempic [${1}].

It is essential to consult the prescribing information for a complete list of side effects, warnings, and precautions. Patients should discuss any concerns about rare side effects with their healthcare provider.

Sources:
[1] FDA. (2021). Ozempic (semaglutide) injection, for subcutaneous use. Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208273s012lbl.pdf
[2] DrugPatentWatch.com. (n.d.). Ozempic (semaglutide) Patent, Legal, and IP Information. Retrieved from https://www.drugpatentwatch.com/drugs/ozempic